ELMWOOD PARK, N.J.,
Sept. 1, 2020 /PRNewswire/ --
BioReference Laboratories, Inc., an OPKO Health company
(NASDAQ:OPK), along with its specialty oncology division, GenPath,
today announced the launch of OnkoSight AdvancedTM, a
next-generation sequencing (NGS) assay that enables revolutionary
deoxyribonucleic acid (DNA) mutational profiling of tumor
samples.
OnkoSight Advanced NGS testing provides targeted gene
content that is aligned with the latest National Comprehensive
Cancer Network (NCCN) and World Health Organization (WHO) guideline
recommendations, to provide critical insights into many of the most
common cancer types. Additionally, OnkoSight Advanced panels each
include key biomarkers: Tumor Mutation Burden (TMB) and Tumor-Only
Microsatellite (MSI), which are critical when profiling advanced
stage tumor malignancies to guide potential immunotherapy.
"OnkoSight Advanced NGS panels are tumor-type specific and
optimized to exclude extraneous gene content, significantly
improving clinical actionability and relevance of the data to
effectively guide real-world oncology patient management," said
Bevan Tandon, M.D.,
Hematopathologist and Molecular Pathologist, Director of Cancer
Genomics at BioReference Laboratories. "Coupled with BioReference
and GenPath's comprehensive oncology test menu, OnkoSight Advanced
empowers physicians to make informed decisions effectively and
efficiently."
"A cancer diagnosis and treatment path are difficult to address
with patients and their families, which drives the importance of
understanding a patient's risk group and accurately diagnosing the
type of cancer, to result in a targeted treatment strategy and
prognosis assessment," said Jon R.
Cohen, M.D., Executive Chairman of BioReference
Laboratories. "The latest advancement from BioReference's oncology
division underscores the commitment to patient-centric care through
our industry-leading result turnaround time with enhanced
accuracy."
For more information about OnkoSight Advanced, visit:
https://www.genpathdiagnostics.com/hcp/onkosight-advanced-tm-next-generation-sequencing/.
About BioReference Laboratories, Inc.
BioReference
provides comprehensive testing to physicians, clinics, hospitals,
employers, government units, correctional institutions and medical
groups. BioReference has been working expeditiously to
develop and offer test services that will yield high quality and
accurate results, including a molecular test for helping with
COVID-19 diagnosis and a serology test to help indicate possible
COVID-19 exposure. The company is in network with the five largest
health plans in the United
States, operates a network of 11 laboratory locations, and
is backed by a medical staff of more than 120 M.D., Ph.D. and
other professional level clinicians and scientists. With a
leading position in the areas of genetics, women's health, maternal
fetal medicine, oncology and urology, BioReference and its
specialty laboratories, GenPath and GeneDx, are advancing the
course of modern medicine. For more information,
visit www.bioreference.com.
About OPKO Health, Inc.
OPKO is a multinational
biopharmaceutical and diagnostics company that seeks to establish
industry-leading positions in large, rapidly growing markets by
leveraging its discovery, development, and commercialization
expertise and novel and proprietary technologies. For more
information, visit www.opko.com.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains "forward-looking
statements," as that term is defined under the Private Securities
Litigation Reform Act of 1995 (PSLRA), which statements may be
identified by words such as "expects," "plans," "projects," "will,"
"may," "anticipates," "believes," "should," "intends," "estimates,"
and other words of similar meaning, including statements regarding
our NGS assay, whether it will prove to be best-in-class or
revolutionary, whether the test will perform or be as accurate as
anticipated, the role and value of the information provided
and its impact on decisions to be made by physicians, and
statements about our result turnaround time and accuracy, as well
as other non-historical statements about our expectations, beliefs
or intentions regarding our business, technologies and products,
financial condition, strategies or prospects. Many factors could
cause our actual activities or results to differ materially from
the activities and results anticipated in forward-looking
statements. These factors include those described in the OPKO
Health, Inc. Annual Reports on Form 10-K filed and to be filed with
the Securities and Exchange Commission and in its other filings
with the Securities and Exchange Commission. In addition,
forward-looking statements may also be adversely affected by
general market factors, competitive product development, product
availability, federal and state regulations and legislation, the
regulatory process for new products and indications, manufacturing
issues that may arise, patent positions and litigation, among other
factors. The forward-looking statements contained in this press
release speak only as of the date the statements were made, and we
do not undertake any obligation to update forward-looking
statements. We intend that all forward-looking statements be
subject to the safe-harbor provisions of the PSLRA.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/opko-healths-bioreference-laboratories-launches-best-in-class-next-generation-sequencing-ngs-assay-301122384.html
SOURCE BioReference Laboratories, Inc.